Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPolar Capital Regulatory News (POLR)

Share Price Information for Polar Capital (POLR)

Share Price is delayed by 15 minutes
Get Live Data
836.00    7.00 (0.84%)
Bid:
835.00
Ask:
837.00
Spread: 2.00 (0.24%)
Market Cap: £789.39m
POLR Live PriceLast checked at - London Stock Exchange

Intraday Polar Capital Share Chart

AUM Update

12 Jan 2017 07:00

RNS Number : 9517T
Polar Capital Holdings PLC
12 January 2017
 

12 January 2017

Polar Capital Holdings plc

AUM Update

 

Polar Capital Holdings plc ("Polar Capital" or the "Group"), the boutique investment management group, today provides its regular quarterly update of its unaudited statement of its Assets under Management ("AUM").

 

Group AUM (unaudited)

 

Polar Capital reports that as at 31 December 2016 its AUM were £8.4bn compared to £7.3bn at the end of March 2016.

 

AUM movement in

nine months to

31 December 2016

USD

GBP

Long only

Funds

Alternative funds

Total

Long only

funds

Alternative funds

Total

AUM at

31 March 2016

$9,378m

$1,054m

$10,432m

£6,531m

£734m

£7,265m

Net subscriptions

/ (redemptions)

$(722)m

$56m

$(666)m

£(493)m

£45m

£(448)m

Market movement

and performance

$653m

$(45)m

$608m

£1,506m

£84m

£1,590m

Total AUM at

31 December 2016

$9,309m

$1,065m

$10,374m

£7,544m

£863m

£8,407m

 

Comment

 

In mid-December we released our interim results and at the time provided guidance that the US election result in November had triggered a noticeable change in flows into our funds. December has continued in the same vein that November finished and it is pleasing to report that more than £100m of net inflows were received in the month into our products, giving a total net flow for the quarter of over £300m.

 

On a less positive note the performance fees earned in the year were below the level of last year although this was the 16th consecutive year that such fees have been earned.

 

Whilst this was not our best year in terms of overall investment performance, our medium and longer term performance numbers on our UCITS products remain extremely strong, as shown in the table below. Thirteen of our eighteen Lipper rated UCITS funds are top quartile since launch, eight of which are top decile, whilst the other five funds are second quartile (as at 31 December 2016).

 

1 year

3 years

5 years

Since

inception

1st quartile

7 funds

8 funds

6 funds

13 funds

2nd quartile

5 funds

2 funds

2 funds

5 funds

3rd quartile

6 funds

3 funds

1 fund

0 funds

4th quartile

0 funds

1 fund

1 fund

0 funds

 

 

Net performance fees (unaudited)

 

The table below sets out the position relating to net performance fees (after the deduction of staff interests) earned and accrued in the first nine months of the Group's financial year.

 

Performance fees

net of staff allocations

Nine months to

31 Dec 15

Year to

31 Mar 16

(year-end)

Nine months to

31 Dec 16

Received

£3.0m

£3.0m

£1.1m

Accrued but not yet earned in funds with year ends on or before the financial year end

-

-

-

Total net performance fees

£3.0m

£3.0m

£1.1m

 

 

 

For further information please contact:

 

Polar Capital

Tim Woolley (CEO)John Mansell (COO)

+44 (0)20 7227 2700

Canaccord Genuity - Nomad and Joint Broker

Simon Bridges (QE)

Andrew Buchanan

Kit Stephenson

+44 (0)20 7523 8000

 

Peel Hunt - Joint Broker

Guy Wiehahn

+44 (0)20 7418 8893

Camarco

Ed Gascoigne-Pees

 

+44 (0)20 3757 4984

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
UPDEAXFFFFDXEFF
Date   Source Headline
20th Feb 20194:54 pmRNSIssue of Equity
18th Feb 201911:09 amRNSHolding(s) in Company
4th Feb 20199:43 amRNSBlock listing Interim Review
1st Feb 201911:41 amRNSTotal Voting Rights
29th Jan 20194:41 pmRNSSecond Price Monitoring Extn
29th Jan 20194:35 pmRNSPrice Monitoring Extension
28th Jan 20195:45 pmRNSIssue of Equity
28th Jan 20195:30 pmRNSDirector/PDMR Shareholding
10th Jan 201910:19 amRNSDirector/PDMR Shareholding
10th Jan 20197:00 amRNSAUM Update
2nd Jan 20199:49 amRNSTotal Voting Rights
12th Dec 20184:00 pmRNSIssue of Equity
27th Nov 20184:40 pmRNSSecond Price Monitoring Extn
27th Nov 20184:35 pmRNSPrice Monitoring Extension
26th Nov 20187:00 amRNSUnaudited Interim Results
22nd Nov 20185:00 pmRNSDirectorate Change
5th Nov 20187:01 amRNSNotice of Results
5th Nov 20187:00 amRNSChange of Nominated Adviser and Broker
1st Nov 20187:00 amRNSTotal Voting Rights
25th Oct 20185:26 pmRNSIssue of Equity
24th Oct 20184:52 pmRNSDirector/PDMR Shareholding
17th Oct 20185:49 pmRNSIssue of Equity
15th Oct 201812:38 pmRNSForm 8.3 - Jardine Lloyd Thompson Group Plc
12th Oct 20182:52 pmRNSForm 8.3 - Jardine Lloyd Thompson Group Plc
11th Oct 20184:42 pmRNSIssue of Equity
11th Oct 20187:01 amRNSCrystallisation of business unit & issue of shares
11th Oct 20187:00 amRNSAUM Update
3rd Oct 201810:24 amRNSForm 8.3 - Jardine Lloyd Thompson Group Plc
19th Sep 201811:52 amRNSForm 8.3 - Jardine Lloyd Thompson Group
18th Sep 201812:02 pmRNSForm 8.3 - Realm Therapeutics PLC
17th Aug 20189:27 amRNSDirectorate Change
6th Aug 20187:00 amRNSBlock listing Interim Review
1st Aug 20187:00 amRNSTotal Voting Rights
31st Jul 20185:57 pmRNSIssue of Equity
31st Jul 201811:29 amRNSDirector/PDMR Shareholding
25th Jul 20183:38 pmRNSDirectorate Change
25th Jul 20183:26 pmRNSResult of AGM
19th Jul 201811:13 amRNSForm 8.3 - Consort Medical Plc
18th Jul 20184:21 pmRNSDirector/PDMR Shareholding
18th Jul 201811:50 amRNSForm 8.3 - Consort Medical Plc
17th Jul 201810:58 amRNSForm 8.3 - Consort Medical Plc
16th Jul 20183:44 pmRNSDirector/PDMR Shareholding
12th Jul 201811:50 amRNSForm 8.3 - Consort Medical Plc
12th Jul 20187:00 amRNSAuM Update
11th Jul 201811:06 amRNSForm 8.3 - Consort Medical Plc
3rd Jul 20186:27 pmRNSHolding(s) in Company
3rd Jul 20186:20 pmRNSIssue of Equity
3rd Jul 201812:07 pmRNSForm 8.3 - Consort Medical Plc
2nd Jul 201810:23 amRNSTotal Voting Rights
29th Jun 20187:00 amRNSBlock Listing Application

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.